rekeland

  1. Kalliope

    Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study - 2020 - Rekeland, Mella, Fluge et al

    published in frontiers in Medicine - Family Medicine and Primary Care Results: The overall response rate by Fatigue score was 55.0% (22 of 40 patients). Fatigue score and other outcome variables showed significant improvements compared to baseline. The SF-36 Physical Function score increased...
    • Kalliope
    • Thread
    • 2020 clinical trial cyclophosphamide fluge hla-dqb1 me/cfs mella norway paper phase ii rekeland
    • Replies: 130
    • Forum: ME/CFS research
  2. Kalliope

    Clinical Therapeutics: Rituximab Serum Concentrations and Anti-Rituximab Antibodies During B-Cell Depletion Therapy for CFS/ME - Rekeland,Mella et al

    Rituximab Serum Concentrations and Anti- Rituximab Antibodies During B-Cell Depletion Therapy for Myalgic Encephalopathy/Chronic Fatigue Syndrome Rekeland, Fluge, Mella et al (only the abstract is available for now) Findings There were no significant differences in mean serum rituximab...
    • Kalliope
    • Thread
    • 2018 fluge me/cfs mella paper rekeland rituximab treatment
    • Replies: 4
    • Forum: ME/CFS research
  3. A

    Drs Fluge and Rekeland to speak at IIME Conference

    Conference speaker news: http://www.investinme.eu/IIMEC13-news-180105.shtml
Back
Top Bottom